Drug Trial Radar · NCT04899115
VE303 for Treatment of Hepatic Encephalopathy (HE)
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Aug 6, 2021
Primary completion
Apr 10, 2023
Study completion Aug 30, 2023
Sponsor
- Lead sponsor
- Patricia BloomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vedanta Biosciences, Inc.; American College of Gastroenterology; American Association for the Study of Liver Diseases
- First posted
- May 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy. Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the study drug (placebo vs.VE303). There will be visits as well as other procedures to collect blood and stool samples, and have tests of your cognition (thinking) for this research study. The hypothesis is that VE303 will safely and effectively improve cognitive function in patients with a history of overt hepatic encephalopathy.
Conditions
- Cirrhosis
- Hepatic Encephalopathy
Interventions
PlaceboDrug
Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
VE303Drug
Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days. The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.
oral vancomycinDrug
All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Serious Adverse Events up to Week 6Time frame: Week 6
- Change in Psychometric Hepatic Encephalopathy Score (PHES) as a Measure of Cognitive Function From Pre-vancomycin to Week 6Time frame: baseline (pre-vancomycin), Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.